What's breaking now, across thousands of outlets.
Researchers from Cambridge and Basel have developed small molecules that could make cancer immunotherapies more effective. They work in two ways: they prompt macrophages to engulf cancer cells and alter the surrounding tissue, reducing its ability to suppress immune attacks on the tumor.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
(MedPage Today) -- The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance…
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key…
Astra Health's five founding members, who serve more than half a million patients annually, hope to improve quality and trim costs at scale while maintaining their independence.
The Trump administration is cracking down further on durable medical equipment suppliers as part of its broader push to root out fraud.
